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HLA specific antibodies vary in their pathogenicity and this is likely to be the net effect of constant chain 
usage, quantity, specificity, and affinity.  Here we have measured the affinity of human monoclonal antibodies 
for a range of HLA proteins.  Purified antibodies and ligands allowed dynamic interactions to be measured 
directly by surface plasmon resonance.  Physiochemical differences between pairs of ligands were quantified 
using electrostatic mismatch and hydrophobic mismatch scores. 
All antibodies were characterized by fast on-rates and slow off rates but with a wide range of association rates 
(kon, 3.63-24.25x105 per mol per second) and dissociation rates (koff, 0.99-10.93x10-3 per second).   
Dissociation constants (KD) ranged from 5.9 x10-10M to 3.0 x10-8M. SN320G6 has approximately a twenty-
fold greater affinity for HLA A2 compared with SN607D8, but has a similar affinity for HLA-A2 and B57.  
In contrast, SN607D8 has greater than a two-fold greater affinity for HLA-A2 compared with A68.  Similarly, 
WK1D12 has about a three-fold greater affinity for HLA-B27 compared with B7.  The higher affinity 
interactions correlate with the specificity of stimulating antigen.  This is the first study to directly measure the 
binding kinetics and affinity constants for human alloantibodies against HLA.  
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HLA specific antibodies are a relative barrier to solid organ transplantation.  Higher levels, which typically 
precipitate a cytotoxic crossmatch, can cause hyperacute rejection [1].  Lower levels may be tolerated or be 
associated with acute rejection and/or poor outcome [2][3][4][5][6].   Post-transplantation, the appearance of 
donor HLA-specific antibodies (DSA) is often, but not always, associated with acute or chronic rejection and 
transplant glomerulopathy [7][3][8][9] [10]. The ability of an HLA-specific antibody or antibody mixture (e.g. 
serum) to activate the classical pathway of the complement system appears to be related antibody 
pathogenicity, although this functionality is not necessarily proportional to measured antibody level [11] [12] 
[13] [14].  Antigen specificity (or the degree of expression of the target antigen) is a further important criterion 
related to pathogenicity as, for example, transplantation can be successful in the presence of cytotoxic positive 
crossmatches due to HLA Class II antibodies [15].  
 
The specificity of HLA antibodies is defined by reaction patterns against different alleles sharing specific 
amino acid residues [16]. These are generally considered to be the nominal epitopes allowing binding of the 
antibody and tend to be reduced to the minimal number of required residues, sometimes to a single amino 
acid.  It has been suggested that the critical interactions for binding involve those residues within a 3Å diameter 
patch, termed an eplet [17] [18].  However, the exact conformation and orientation of the interaction has yet 
to be shown for any HLA protein-anti-HLA antibody complex [19].  The footprint of the antibody 
complementarity determining regions (CDRs) can be up to 900 Å2 in surface area [20] [21], and therefore a 
larger number of amino acid residues within the HLA protein, perhaps up to 25, will likely be involved in 
determining the nature of the interaction, imparting both specificity and affinity.  Importantly, the reactivity 
of HLA proteins with antibody can vary even when sharing the critical epitope/eplet. It is speculated that the 
difference in reactivity is due to a difference in release of binding energy which is proportional to the total 
surface area of interaction [22] [23].  The immunogenicity of the HLA antigen, defined as its ability to 
evoke/stimulate a de novo antibody response can also vary and is believed to be related to electrostatic and 
hydrophobic properties of amino acid residues within polymorphic regions of the HLA protein [24] [25] [26]. 
 
Current solid phase single antigen bead assays measure mean fluorescence intensity (MFI) and this readout is 
often used to estimate amounts of antibodies, although this has not been validated.  High value MFIs will have 
components relating to both higher absolute antibody concentrations and to stronger antibody binding 
(affinity).  Resolving the distinction between concentration and affinity is important because affinity 
measurements are likely to provide a greater insight into antibody function.  During the immune response, the 
affinity of antibodies typically increases by affinity maturation. This is generated via somatic hypermutation 
of immunoglobulin gene segments, leading to clonally selected variations in amino acid sequences that favor 
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increased binding to target antigens [27].  Only one study has previously determined the affinity of HLA 
antibodies, and that was of mouse monoclonal antibodies against human HLA-A2 protein expressed on human 
B-cell lines. That study shows marked differences in affinity between Fab fragments from two separate 
monoclonal antibodies (determined to be in the micromolar and nano-molar range, respectively), which were 
due to difference in the dissociation rates [28]. The authors used a saturation binding technique with radio-
labeled antibodies.   Our study is the first to directly measure the affinities of human allo-antibodies against 
HLA.   
 
Through the use of real time biosensor techniques (by surface plasmon resonance), we have been able to 
measure binding kinetics and the affinity constants of antibodies against different HLA proteins that share 
epitopes/eplets but differ in adjacent residues.  This approach was used to determine quantitatively the 
importance of epitope configurations in relation to affinity. Here, we used this technique to measure the affinity 
of clinically relevant anti-HLA antibodies. 
 
2. Material and Methods 
 
2.1. Biotinylated soluble recombinant HLA proteins.   
 
Biotinylated soluble recombinant HLA proteins (sHLA) were provided by Pure Protein LLC (Oklahoma City, 
OK, USA) [29].  Products of the following genes were studied; HLA-A*01:01, A*02:01, A*68:01, B*57:01, 
B*07:02, and B*27:05.  We will refer to these proteins as HLA-A1, A2, A68, B57, B7, and B27, respectively, 
for simplicity. The concentration of the purified biotinylated molecules was determined using the Micro BCA 
protein assay kit (Thermo Fisher Scientific, Rockford, IL) using bovine gamma globulin (Sigma; Poole, UK) 
as a protein standard. 
 
2.2.  Human monoclonal HLA-specific antibodies. 
 
Human monoclonal HLA-specific antibodies (mAbs) were secreted by human hybridomas produced by 
Epstein-Barr virus (EBV) transformation of B-lymphocytes from HLA antibody positive multi-parous women 
(sensitised during pregnancy), followed by fusion and sub-cloning of antibody producing EBV lines (Table 
1). SN607D8 and SN203G6 were derived from the same multiparous donor (HLA type A*24 A*29, B*07, 
B*44, C*07, C*16) sensitized during pregnancy (child’s HLA type A*02, A*29, B*44, B*57).  WK1D12 was 
derived from a female donor (HLA type A*01, B*08, C*07) sensitized during pregnancy (child’s HLA type 
A*01, A*11, B*08, B*27, C*01, C*07). 
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Antibody-containing supernatants were dialyzed (8,000 MWCOSpectra/Por® Dialysis) against PBS 
overnight. The supernatants were further processed by affinity chromatography using HLA protein 
immobilized on Sepharose beads [29] and ion-exchange chromatography using Q-Sepharose. HLA-A2 (from 
A*02:01) and B7 (from B*07:02) were separately coupled to cyanogen bromide activated Sepharose and the 
resulting columns were used to enrich mAbs SN203G6 and SN607D8, and WK1D12 respectively.   Overall 
this approach yielded highly purified monoclonal IgG and avoided contamination with residual bovine IgG 
and other serum components from the hybridoma culture medium. The homogeneity of the purified IgG was 
confirmed via SDS-PAGE using 4-12% gradient polyacrylamide gels. The concentration of purified antibodies 
was determined using Lowry’s assay [30]. CDC defined antibody specificities were confirmed in a single 
antigen bead assay (One Lambda, Canoga Park, CA) as per manufacturer’s instructions.  Dose response curves 
from antibody doubling dilution series were used to calculate effective concentrations that gave 50% of 
maximal MFI signal (EC-50).  Hill-type EC-50 values were calculated using curve fitting performed in 
MATLAB. 
 
2.3. Surface Plasmon Resonance. 
 
Sensorgrams were obtained using the Bio-Rad Proteon XPR36 biosensor platform [13] [14].  2.5 µg/ml of 
biotinylated HLA protein was immobilized on neutravidin-coated sensor chips (ProteOn™ NLC Sensor Chip 
#1765021) with a flow rate of 25 µl/min over 300 seconds.  Purified monoclonal HLA-specific antibodies 
were flowed over the chip at a rate of 25 µl/min (slowest rate for the equipment to allow maximum binding) 
for 960 seconds to obtain equilibrium phase (where the sensorgram of binding phase plateaus) and at 37oC in 
the association phase to represent physiological binding temperatures.   Following this, the running buffer 
(PBS containing 0.05% Tween 20) was passed over for 960 seconds at a flow rate of 25 µl/min for the 
dissociation phase. Interactions of all three HLA-specific antibodies were studied in duplicate over a range of 
six different concentrations (3.125 to 100 nM) against the same surface concentration of immobilized HLA 
protein. 
 
The data obtained from the sensorgrams were modelled using an implementation of differential evolution [31] 
on MATLAB software (Mathworks®) with the simulation tool FACSIMILE (MCPA Software) [32]. Together 
these allow for curve fitting and simultaneous determination of kinetic association (kon) rates, dissociation (koff) 
rates and the Dissociation Constant KD (as the ratio of the dissociation,koff, and association,kon, rate constants).  
 
2.4.  Molecular differences between the allele pairs. 
 
The PyMOL Molecular Graphics System, Version 1.1 Schrödinger, LLC was used to model the 
crystallographic structures of HLA-A2 (PDB ID: 3MRK), A68 (PDB ID: 4HWZ), B27 (PDB ID: 10GT 
identifier), B57 (PDB ID: 2YPK), and B7 (PDB ID: 3VCL). These structural diagrams were used to show 
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molecular differences between each allele pair shown.  We considered the area within a 15 Å radius around 
the designated epitope on the HLA molecule examined (as compared to the whole protein), since this 
corresponds to the maximum radius of the antibody recognition site comprising the cognate antibody paratope 
[18]. Within this putative contact area on the HLA molecule the number of amino acid differences, electrostatic 
mismatch score (EMS), and hydrophobic mismatch score (HMS) [26] [24], were estimated to quantify 
physiochemical differences between pairs of HLA proteins.  Two sets of comparisons were made, including 





3.1.  Determination of binding kinetics for human monoclonal HLA-specific antibody-HLA protein 
interactions. 
 
The sensograms illustrating the interactions between human HLA-mAbs and immobilized HLA-proteins are 
distinct, specific and reproducible (Figure 1).  Differences in signal (defined by response units, RU) and 
kinetics (kon and koff values) were observed for different antigen-antibody interactions (data given in Table 2).  
Consistent with the known specificities of these antibodies (Table 1) SN607D8 showed binding to HLA-A2 
and A68 and not to HLA-A1; SN230G6 bound to HLA-A2 and B57 and not to HLA A1; WK1D12 bound to 
HLA-B7 and B27 and not to HLA-A1. 
Modelling of the sensorgram data was optimised using MATLAB together with the simulation tool 
FACSIMILE, with the kinetic parameters determined across both phases using the full dynamic data.  
The quality of the fit of the model to the data to provide the kinetic constants was assessed visually 
(Figure 2) and quantitatively within MATLAB/FACSIMILE via the residual sum of squares. The 
fitting process yielded fits with low residual sum of squares in which typically the estimated SPR signal 
remained within the sensorgram signal throughout the experiment (Figure 2).  The binding kinetics modelled 
varied greatly between the three antibodies against the HLA proteins which they are known to recognize 
(Table-2).  All are characterized by fast on-rates and slow off rates but there is a wide range in the magnitude 
of these parameters for the reactions tested.  The association rates (kon) varied between 3.63 and 24.25 x105 
per mol per second and the dissociation rates (koff) varied between 0.99 and 10.93 x10-3 per second.  The 
dissociation constant (KD) values obtained were in the range of 0.1-10 nM (Table 2). 
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SN230G6 has an affinity (inverse of KD) for both HLA-A2 and B57 around an order of magnitude greater than 
that of SN607D8 for HLA-A2 or A68; against just HLA-A2, the former exhibits a twenty-fold greater affinity 
compared with the latter.  Figure 1 shows that SN230G6 has a faster on-rate, and reaches a higher equilibrium 
level than SN607D8.  The greater affinity of SN230G6 for HLA-A2 is also seen with a dose-response 
experiment via bead assay:  SN607D8 requires about a ten-fold greater concentration to reach half-maximal 
binding (EC-50) compared with SN230G6 (Table 2). EC-50 analysis was not able to distinguish any difference 
in the binding of these two antibodies to HLA-A2 compared to either A68 or B57 (SN607D8 and SN230G6, 
respectively).  In contrast, the biosensor assay showed that SN607D8 has approximately 2.5 times the affinity 
for HLA-A2 compared with A68.  SN230G6, on the other hand, has similar affinities for HLA-A2 and B57 
(1.33-fold difference).  We also found that WK1D12 has about a three-fold greater affinity for HLA-B27 
compared to B7.  Thus, in the two cases where the stimulating HLA for the antibody is known, the affinity is 
greater for that allele compared to a different allele but one which shares the critical binding motif.  
 
3.2.  Influence of molecular difference on binding affinities. 
 
Figure 3 shows the structural differences between the HLA pairs within a radius of 15Å about the notional 
epitope or eplet that associates with the reactivity of each antibody.   This corresponds to the binding footprint 
as described by Duquesnoy et al. [18].   Within this area (900Å2) we counted the number of amino acid residue 
differences, and the EMS and HMS for each pair (data given in Table 3).   All the designated epitopes/eplets 
lie adjacent to the peptide-binding groove and it is not certain how, or indeed if substitutions within the groove 
could contribute to the binding of these alloantibodies.  Therefore, we have calculated the differences between 
the HLA pairs with and without the internal binding groove residues.  These results are given in Table 3.   It 
is immediately obvious that none of these physical differences correlate with the affinity differences between 
any of the HLA pairs and their respective antibodies.  The largest number of amino acid differences of the 
antigen pairs examined is seen between HLA-A2, and B57, this is unsurprising as antigens encoded by 
different HLA gene loci would be reasonably expected to show increased variation. However, the difference 
in SN230G6 binding to these individual antigens is lowest. SN607D8 and WK1D12 exhibit similar differences 










This paper describes the first use of a real time, label free biosensor technique to characterize biophysical 
properties of human, monoclonal, HLA-specific antibodies.  We were able to show distinct KD values for 
different HLA antibody/HLA allele combinations, in the order of 0.1nM to 10.0nM.  We have shown that the 
signal obtained displays the expected HLA specificity and we can discern a distinct signal for low nanomolar 
concentrations of these human monoclonal HLA-specific antibodies.  The dissociation constants obtained for 
mAbs in this study are similar to previously reported values for target ligands [33] [34] [28].  SPR has been 
used to detect and study the binding interactions of dsDNA-specific antibodies in patients with SLE [35] while 
a recent study of ninety-nine patients showed the avidity of dsDNA antibodies correlates with disease activity 
of lupus nephritis [36].  It is therefore reasonable to assume that the characteristics of the HLA antibodies we 
describe here relate to their pathogenicity and are therefore likely to be of clinical relevance.  Further to this, 
a given antibody may differ in its pathogenicity depending on its target allele because its affinity will vary 
accordingly.  Duquesnoy et al [22] have shown that the same monoclonal antibody can be associated with 
different degrees of complement-dependent cytotoxicity depending on the HLA allele expressed on the target 
cell.  Those authors speculated that this involved target affinity differences and here we prove that such affinity 
differences do exist. 
 
The two human antibodies (SN230G6 and SN607D8) which bind to HLA-A2 were derived from the same 
multiparous woman.  SN607D8 is clearly the consequence of HLA-A2 immunization whereas SN230G6 could 
be the result of HLA-A2 or B57 immunization, or possibly by both as they were co-expressed by the sensitizing 
individual. The affinity of SN230G6 for HLA-A2 (epitope 62GE) is 20-fold greater than of SN607D8 for 
HLA-A2 (epitope 142TKH).  Kushihata et al [37], measured the CDC activity of these mAbs and showed a 
ten times higher CDC reactivity by SN230G6 compared to SN607D8 against the same target cell.  We showed 
a similar difference of their EC-50 values in a single antigen bead assay (Table 2).  This EC-50 analysis also 
demonstrates very starkly that the amount of serum antibody that binds to each bead is not a simple reflection 
of its serum concentration; it is also affinity dependent.  The affinity difference for HLA-A2 is related to 
differences in kinetic rates; the association rate is faster and the dissociation rate slower with SN230G6.  The 
variation in affinity of a single mAb, SN607D8, for the two serologically related antigens, HLA-A2 and A68, 
could be due to interaction with different residues in the immediate vicinity of the distinguishing epitope which 
in turn may alter the spatial orientation and steric accessibility of the epitope from one antigen to the other.  
Thus, both the best fit and surface area involved in the overall interaction may determine the stability of 
binding [19].  Although the difference in dissociation constant is relatively small (within one order of 
magnitude), the kinetic parameters (association and dissociation rates) differed more widely.  Therefore, for 
comparisons, dissociation constants alone may not give a full picture.  Close inspection of our data reveals 
that while the on-rates for binding of one antibody to different HLAs may be similar, the overall affinity may 
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be more dependent on the dissociation rate, and this may be markedly slower for the target HLA that 
corresponds to the immunizing antigen (Figure 4).  These are useful observations as current solid phase assays 
do not distinguish these differences in binding characteristics which may be important in determining 
biological reactivity of the HLA-specific antibodies and their downstream effects.  Thus, the higher affinity 
associated with a stimulating antigen suggests that a repeat antigen mismatch transplant might impart a 
greater risk than if only the epitope were repeated in an antibody incompatible transplant. 
 
The high degree of sequence homology between alleles (and between the products of different loci) results in 
cross-reactivity due to shared immunogenic epitopes and eplets.  We have shown that despite sharing a critical 
sequence, which confers specificity, substitutions in other parts of the target molecule can result in large 
affinity differences.   It was not obvious which of the mismatched residues or their physiochemical properties 
accounted for these differences and this is most likely because we do not know the orientation of binding or 
the exact interface surfaces.  This is also illustrated by the similar affinity of SN230G6 for HLA-A2 and B57, 
products of different loci, which implies that there might be an almost identical antibody-accessible surface 
on these two molecules.  We are unable to resolve whether or not non-exposed residues in the peptide binding 
groove contributed to the binding kinetics of any of the antibodies studied, either directly or by virtue of the 
peptides presented.  Although SN607D8 binds differently to HLA-A2 and A68, the only differences between 
these alleles within 15A of the presumed critical eplet (142TKH) are within the peptide binding groove.    
Taken together, this suggests that the model by which antibody binding is precisely centered around an eplet 
[18] may not be correct, at least for these antibodies.  Ultimately these issues are likely to be resolved by 
structural imaging experiments.    
 
In conclusion, the binding assay described here possesses advantages over current assays since it captures a 
broader, real-time picture of the binding events and levels, compared with simpler end-point assays such as 
Luminex single antigen bead assay, ELISA and flow cytometry.  There are, of course difficulties with SPR, 
the requirement for highly purified antibodies because the sensor chip surface is very sensitive to non-specific 
binding.   By purifying the antibodies, we have been able to directly measure the binding kinetics of HLA 
antibodies and these measurements are likely to be critical in the understanding of the pathogenicity of these 
antibodies.   Another exciting opportunity lies in the ability of SPR experiments to obtain thermodynamic data 
(such as free energy released) for these interactions, yielding further parameters of potential physiological 
value plus deepening our understanding of antibody function and biophysics.  Our experiments have also 
underlined the limitations of our knowledge of how alloantibodies bind to their HLA targets.  Although we 
can now show whether or not a particular antibody binds differently to its known ligands and measure the 
magnitude of any variation, we do not yet know completely the molecular basis underlying such differences. 
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mAb Immunizing HLA Bead assay-defined HLA specificities* Epitope designation  Isotype 
SN607D8 A2 
A*02:01/03/06, A*68:01/02, A*69:01 
142TKH IgG1, κ 
SN203G6 A2 and/or B57 A*02:01/03/06, B*57:01/03, B*58:01 62GE IgG1, λ 
WK1D12  B27 B*27:05/08, B*07:02, B*13:02, 
B*40:01/02/06, B*81:01 
163EW IgG1, κ 
 
 
Table 1: Characteristics of IgG human monoclonal HLA-specific antibodies. Epitope designations use the 
nomenclature from the HLA epitope registry (www.epregistry.br) and are based on reaction pattern rather than 
















  EC-50 
EC-50 
ratio 





SN607D8 A2   2   4.6x105 5.6x10-3 1.22x10-8 1.2x10-8  
      0.8  4.05x105 4.9x10-3 1.21x10-8  2.47 
  A68   1.6   3.23x105 9.45x10-3 2.93x10-8 3.0 x10-8  
        4.05x105 12.4x10-3 3.07x10-8  
 
SN230G6 A2   0.18   23.2x105 1.31x10-3 
5.63 x10-
10 
5.9 x10-10  




  B57   0.15   28.7x105 1.88x10-3 
6.56 x10-
10 
7.8 x10-10  





WK1D12 B27   ND    9.8x105 1.02x10-3 1.04 x10-9 1.04 x10-9  
         9.1x105 0.95x10-3 1.04 x10-9  3.01 
  B7   ND    14.2x105 3.45x10-3 2.43 x10-9 3.12 x10-9  
            9.8x105 3.72x10-3 3.81 x10-9   
 
Table 2:  Difference in kinetic rates and dissociation constants for mAbs interaction with different alleles.  
Each shown kon, koff, and KD value is from two separate binding experiments. The original sensitizing antigens 









  Number of amino 
acid residue 
differences between 










All Exposed Ratio of KD 




12.09 12 2.47 




35.7 22.7 1.33 




38.6 27 3.01 
 
Table 3: Molecular and physiochemical differences between alleles in the region described by a 15 
Å radius around the presumed epitope.  *’All’ includes those amino acid residues within the peptide 
binding groove and exposed excludes these when comparing between the two antigens listed on each 















Figure 1:  Binding kinetics of three of human mAbs to HLA.  a. SN607D8; b. SN230G6; c.WK1D12.  The 
sensorgrams show antibody binding at six concentrations as shown in the top right panel.  Note the scale of 
the y axes is the same for and b (max 300 RU) and different for c (max 600RU). 
 
Figure 2: Data fitting examples (solid black lines) shown (SN607D8 binding to HLA-A2 (a) SN230G6 to 
HLA-B57 (b) and WK1D12 to HLA-B27 (c).   
 
Figure 3:  Structural differences between HLA pairs, each recognized by the same antibody (a. SN607D8; b. 
SN230G6; c. WK1D12).   Red positions indicate the amino acid residues that associate with the specificity of 
the antibody and define the notional epitope.   On the left-hand ribbon diagrams, yellow shows the area within 
a radius of 15A from each such epitope and suggest a binding footprint of the antibody.  Yellow residues on 
the right marks the amino acid differences within this footprint for each HLA pair. 
 
Figure 4: Relationships between association (on) and dissociation rates (off) for the three mAbs and their 
target ligands, as follows:   SN607D8+HLA A2;  SN607D8+HLA A68; ⬜ WK1D12+HLA B7;  
WK1D12+HLA B27; SN230G6 + HLA A2 and HLA B57.  Where the target HLA and the HLA present 
during immunization are the same the symbols in the figure are filled (HLA A2 and B57 reactions with 
SN230G6 are identified).  Each of the duplicate results are shown. 
 
 
 
